Inclusion Criteria:

          -  Histologically or cytologically documented incurable or metastatic solid tumors of the
             following types: melanoma, UC, ovarian cancer, colorectal cancer, breast cancer (HR+),
             or prostate cancer.

          -  Disease has progressed after at least one available standard therapy or no additional
             curative therapies are available.

          -  Measurable disease per RECIST v1.1

          -  Eastern cooperative oncology group (ECOG) performance status of 0 or 1

          -  Adequate hematologic and end organ function determined within 30 days prior to
             enrollment.

          -  Disease-specific criteria related to the specific tumor type are required.

        Note: There are additional inclusion criteria. The study center will determine if you meet
        all of the criteria.

        Exclusion Criteria:

          -  Known clinically significant liver disease, including active viral, alcoholic, or
             other hepatitis, cirrhosis, and/or inherited liver disease

          -  Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases

          -  Uncontrolled or symptomatic hypercalcemia

          -  Pregnancy, lactation, or breastfeeding

          -  Prior allogeneic stem cell transplant or solid organ transplant

          -  Prior chimeric antigen receptor therapy or other genetically modified T cell therapy

          -  Active HIV, Hepatitis B, or Hepatitis C infection

          -  Active tuberculosis

          -  Severe infection within 2 weeks prior to enrollment

          -  Major surgical procedure within 4 weeks prior to enrollment or anticipation of need
             for a major surgical procedure during the study.

        Note: There are additional exclusion criteria. The study center will determine if you meet
        all of the criteria.